Bayer AG, the German pharmaceutical and agricultural company based in Leverkusen, has formally sought the attention of the United States Supreme Court. The company is optimistic that a ruling from the highest court could significantly mitigate the ongoing wave of lawsuits related to glyphosate, a widely used herbicide. However, it remains uncertain when the court will decide to take up the case, or if they will choose to do so at all. The legal contention primarily revolves around conflicting decisions made by federal appellate courts concerning the alleged cancer risks associated with glyphosate-based weed killers. Central to this issue is the question of whether federal law regarding warning labels for herbicides supersedes state laws. The U.S. Environmental Protection Agency (EPA) has maintained that glyphosate is safe for use when applied as directed, having approved its product labeling without any accompanying warnings. Bayer's troubles with glyphosate originated with its acquisition of Monsanto in 2018 for over $60 billion. This purchase brought with it an array of legal challenges, including the first negative ruling against Bayer in the same year, which triggered a torrent of lawsuits costing the company billions in settlements and legal fees. As of January 31, 2025, Bayer has settled approximately 114,000 out of around 181,000 claims related to glyphosate, with many cases either settled or not meeting the criteria for settlement. In 2022, Bayer faced another setback when the Supreme Court declined to hear an appeal related to glyphosate, leaving a lower court's ruling intact. This latest move to the Supreme Court signifies Bayer's ongoing struggle to address the legal and financial ramifications stemming from its glyphosate products, amidst a backdrop of public concern over the chemical's safety and potential health impacts.